Profound Medical (PROF) Net Income towards Common Stockholders (2019 - 2026)

Profound Medical has reported Net Income towards Common Stockholders for 8 years, with the latest figure at $7.1 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 34.23% year-over-year to $7.1 million; the trailing twelve-month figure through Mar 2026 stood at $60.3 million (up 33.73% YoY), and the FY2025 full-year result was $42.6 million, up 53.04% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at $7.1 million, down from $77.0 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $77.0 million in Q4 2025, with the low at -$48.6 million in Q4 2023.
• Average Net Income towards Common Stockholders over 5 years is $2.4 million, with a median of $5.5 million recorded in 2023.
• Year-over-year, Net Income towards Common Stockholders tumbled 269.41% in 2024 and surged 262.85% in 2025.
• Tracing PROF's Net Income towards Common Stockholders over 5 years: stood at -$47.4 million in 2022, then retreated by 2.49% to -$48.6 million in 2023, then soared by 204.24% to $50.7 million in 2024, then surged by 51.85% to $77.0 million in 2025, then slumped by 90.84% to $7.1 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $7.1 million (Q1 2026), $77.0 million (Q4 2025), and -$8.0 million (Q3 2025), per Business Quant data.

Peer Comparison